Side-by-side · Research reference
SemaxvsThymosin α-1
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AHuman-MechanisticDraft12/39 cited
BPhase 3Reviewed8/39 cited
Semax
Cognitive enhancer · Russian Pharma
Intranasal · 2–3×/day during cognitive demand
Thymosin α-1
Immune modulator · Approved (some countries)
SQ · 2× weekly · 6+ months for chronic indications
01Mechanism of Action
Parameter
Semax
Thymosin α-1
Primary target
BDNF / NGF expression + monoamine modulationKaplan 2017
Toll-like receptor 9 (TLR9) + T-cell maturation pathwayCamerini 2001
Pathway
↑ BDNF + NGF synthesis + 5-HT modulation → neuroplasticity + anxiolysis + cognitive enhancementKaplan 2017
TLR9 activation → ↑ IFN-α + IL-2 + IFN-γ → enhanced T-cell function + dendritic cell maturationIyer 2007
Downstream effect
Improved memory + attention; reduced anxiety; neuroprotection in ischemiaKaplan 2017
Restored T-cell function, improved viral clearance, anti-tumour adjuvant effectsIyer 2007
Feedback intact?
—
—
Origin
Synthetic 7-AA peptide derived from ACTH(4-7) with C-terminal Pro-Gly-Pro stabilising tailKaplan 2017
Synthetic 28-AA peptide identical to natural Tα-1 isolated from thymus extractCamerini 2001
Antibody development
—
—
02Dosage Protocols
Parameter
Semax
Thymosin α-1
Frequency
2–3× per day during cognitive demand
2× weekly (Mon/Thu typical)
Lower / starter dose
100 mcg / dose
0.8 mg per injection
Evidence basis
Human-mechanistic + Russian clinicalKaplan 2017
Phase 3 + approved (35+ countries as Zadaxin)Iyer 2007
Duration
10–14 day cycles, repeated PRN
6–12 months for chronic indications
Reconstitution
Pre-formulated nasal spray (commercial); research vial: bacteriostatic water
Sterile water for injection per vial label
Timing
Morning + early afternoon
No specific time
Half-life
Short plasma; CNS effect lasts ~3–6 hr
~2 hours plasma; tissue effect days
04Side Effects & Safety
Parameter
Semax
Thymosin α-1
Nasal irritation
Mild burning or congestion (transient)
—
Sleep disruption
Late-day dosing may interfere with sleep
—
Headache
Uncommon, transient
—
Long-term safety
Limited Western RCT data
—
Pregnancy / OB
Avoid
Avoid
Injection site reaction
—
Erythema, mild discomfort
GI symptoms
—
Rare nausea
Fatigue
—
Common during initial weeks
Fever / flu-like
—
Mild interferon-like response possible
Autoimmune
—
Theoretical risk; caution in active autoimmune disease
Cancer risk
—
No signal — used as adjuvant in oncology
Absolute Contraindications
Semax
- ·Pregnancy / breastfeeding
Thymosin α-1
- ·Pregnancy / breastfeeding
- ·Hypersensitivity to peptide
- ·Concurrent immunosuppressant therapy (transplant patients)
Relative Contraindications
Semax
- ·Active psychiatric instability
- ·Concurrent strong stimulants
Thymosin α-1
- ·Active autoimmune disease
- ·Severe immunocompromised state without supervision
05Administration Protocol
Parameter
Semax
Thymosin α-1
1. Form
Pre-formulated nasal spray (commercial) or research vial reconstituted with bacteriostatic water.
Add 1 mL sterile water per 1.6 mg vial → 1.6 mg/mL.
2. Administration
Intranasal — 2–3 sprays per nostril per dose. Tilt head slightly back.
SQ — abdomen, thigh, or upper arm. Rotate sites.
3. Timing
Morning + early afternoon. Avoid evening (sleep disruption).
2× weekly, e.g. Monday + Thursday.
4. Storage
Refrigerate after reconstitution; light-protected.
Lyophilised: refrigerate. Reconstituted: refrigerate, use within 24 h.
5. Caveat
Cycle on/off to avoid neurochemical adaptation.
27–31G, 4–8 mm insulin syringe.
06Stack Synergy
Semax
+ Selank
ModerateSemax (cognitive enhancer, BDNF/NGF) and Selank (anxiolytic + immune) form the canonical Russian "neuro stack" — both intranasal peptide bioregulators with complementary axes. Semax for cognitive demand; Selank for stress mitigation.
- Semax
- 200–600 mcg intranasal · morning + afternoon
- Selank
- 150–300 mcg intranasal · midday + early evening
- Primary benefit
- Cognitive enhancement + stress mitigation
Thymosin α-1
— no documented stacks